Aisling Capital is a private equity firm that specializes in growth equity investments in the healthcare sector. The firm focuses on providing capital to commercial-stage companies with a track record of revenue generation. Aisling Capital partners with management teams to help drive value creation through strategic guidance and operational support.

Aisling Capital

Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.

Monte Rosa Therapeutics

Elevation Oncology

Intercept Pharmaceuticals

Nuvation Bio

Poseida Therapeutics

Reneo Pharmaceuticals

Biohaven Pharmaceutical

Biomea Fusion

BridgeBio

Bristol-Myers Squibb

Syros Pharmaceuticals

T2 Biosystems

Talaris Therapeutics

Asensus Surgical

Verona Pharma

ViewRay

Aclaris Therapeutics

ADMA Biologics

Arcus Biosciences

Atreca

Avrobio

COM:AISLINGCAPITAL

Aisling Capital